A Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors

Patient Inclusion Criteria

Patients must meet all of the following inclusion criteria to be eligible for enrollment
into the study:

- Histologically or cytologically confirmed metastatic or unresectable solid tumor.

- Has failed treatment with all standard therapies for their malignancy.

- Adequate Karnofsky Performance Status.

- An expected survival of at least 3 months.

- Adequate organ and bone marrow function.

- Signed informed consent form for study participation prior to screening.

Patient Exclusion Criteria

Patients presenting with any of the following will be excluded in the study:

- Clinically significant disease as defined by the protocol.

- Surgical therapy or other therapies within period as defined by the protocol.

- Any condition that will interfere with compliance with the protocol as determined by
investigator.